West Pharmaceutical Services posted stronger-than-expected second-quarter results, with revenue rising 9.2% year-on-year to $766.5 million, ahead of analysts’ $725.26 million consensus. Adjusted earnings per share climbed 21% to $1.84, also topping forecasts, while organic sales grew 6.8%. Chief Executive Officer Eric Green said the outperformance reflected robust demand for GLP-1 elastomer components, continued conversion to high-value products tied to Annex 1 regulatory requirements, and a gradual normalization of customer ordering patterns. On the strength of the quarter, the company lifted its full-year 2025 revenue outlook to a range of $3.04 billion to $3.06 billion, up from the prior $2.945 billion to $2.975 billion, citing sustained product momentum and favorable foreign-exchange movements. The earnings beat and upgraded guidance sent West Pharmaceutical shares up roughly 22% in pre-market trading.